A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Source abstract
Abstract
Objectives The study aimed to evaluate the prognostic value of systemic inflammation markers [neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), Prognostic Nutritional Index (PNI)] and hepatic inflammation markers [aspartate aminotransferase-to-platelet ratio index (APRI), γ-glutamyl transferase (γ-GT)/alanine aminotransferase (ALT)] in patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and further to develop a novel prognostic score model.Methods A total of 401 cases with HBV-associated HCC who underwent hepatectomy as initial therapy were included in the analysis. Kaplan–Meier was performed to construct survival curves and receiver operating characteristic (ROC) analysis was used to detect the optimal cut-off value of markers. The prognostic score model was constructed using significant inflammation markers in the Cox model. Each factor was given a score of 1 and patients were stratified according to the scores.Results In the Cox model, α-fetoprotein (AFP), ALT, tumour differentiation, maximum size of tumours, TNM stage, PNI and γ-GT/ALT were independently prognostic factors. We established a preoperative inflammation-based prognostic scoring model combining PNI and γ-GT/ALT. The novel preoperative inflammation-based prognostic score was superior (area under the curve [AUC], 0.659) to 7th tumour-node-metastasis (TNM) stage (AUC, 0.600) despite no statistical significance (p = .1036).Conclusion PNI and γ-GT/ALT are independent predictors for prognosis. The novel prognostic score model based on systemic and hepatic inflammation markers is suitable for the prognosis evaluation in patients with HBV-associated HCC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inflammatory Biomarkers in Disease Prognosis · Hepatocellular Carcinoma Treatment and Prognosis · Liver Disease Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology, Peking University International Hospital
Department of Hepatobiliary Surgery, Chinese PLA General Hospital
Department of Oncology, Air Force General Hospital of Chinese PLA
Department of Oncology, Chinese PLA General Hospital
References (50)
Show source-provided references
1. 10.1053/j.gastro.2007.04.06110.1053/j.gastro.2007.04.061 ↗
2. 10.1097/MCG.0b013e3181d46ef210.1097/MCG.0b013e3181d46ef2 ↗
3. 10.1038/nature0132210.1038/nature01322 ↗
4. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
5. 10.1002/cncr.2097610.1002/cncr.20976 ↗
6. 10.1186/1471-2407-14-11710.1186/1471-2407-14-117 ↗
7. 10.1186/1477-7819-12-5810.1186/1477-7819-12-58 ↗
8. 10.1038/bjc.2012.9210.1038/bjc.2012.92 ↗
9. 10.1038/bjc.2012.35410.1038/bjc.2012.354 ↗
10. 10.1097/MD.000000000000673510.1097/MD.0000000000006735 ↗
11. 10.1053/jhep.2003.5034610.1053/jhep.2003.50346 ↗
12. 10.1002/hep.2410510.1002/hep.24105 ↗
13. 10.1097/MD.000000000000548610.1097/MD.0000000000005486 ↗
14. 10.1007/s12072-010-9213-310.1007/s12072-010-9213-3 ↗
15. 10.1007/s00535-009-0050-x10.1007/s00535-009-0050-x ↗
16. 10.1016/j.jhep.2011.12.00110.1016/j.jhep.2011.12.001 ↗
17. 10.1055/s-2007-100712210.1055/s-2007-1007122 ↗
18. 10.4143/crt.2017.12610.4143/crt.2017.126 ↗
19. 10.1111/j.1749-6632.2009.03704.x10.1111/j.1749-6632.2009.03704.x ↗
20. 10.1002/hep.2456310.1002/hep.24563 ↗
21. 10.2174/18715201179601107310.2174/187152011796011073 ↗
22. Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Inflammation and Gastrointestinal Cancers. Springer; 2011. pp. 135–148.
23. 10.1177/011542650502000436910.1177/0115426505020004369 ↗
24. 10.1038/clpt.2011.12210.1038/clpt.2011.122 ↗
25. 10.1016/j.trsl.2012.01.01110.1016/j.trsl.2012.01.011 ↗
26. 10.1016/j.jhep.2012.06.02210.1016/j.jhep.2012.06.022 ↗
27. Shen S-L, Fu S-J, Chen B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21:3802–3809.
28. 10.1007/s00268-008-9552-610.1007/s00268-008-9552-6 ↗
29. 10.1097/TP.0b013e3182187cf010.1097/TP.0b013e3182187cf0 ↗
30. 10.1016/j.jvir.2010.12.04110.1016/j.jvir.2010.12.041 ↗
31. 10.1111/j.1440-1746.2011.06910.x10.1111/j.1440-1746.2011.06910.x ↗
32. 10.1007/s00595-009-4065-y10.1007/s00595-009-4065-y ↗
33. 10.1002/bjs.730510.1002/bjs.7305 ↗
34. 10.1016/S1357-2725(02)00251-010.1016/S1357-2725(02)00251-0 ↗
35. Meng Q-H, Yu H-W, Li J, et al. Inadequate nutritional intake and protein-energy malnutrition involved in acute and chronic viral hepatitis Chinese patients especially in cirrhosis patients. Hepato-gastroenterol. 2009;57:845–851.
36. 10.1016/0167-5699(94)90138-410.1016/0167-5699(94)90138-4 ↗
37. 10.1016/S0140-6736(80)90284-610.1016/S0140-6736(80)90284-6 ↗
38. 10.1097/01.TP.0000437426.15890.1d10.1097/01.TP.0000437426.15890.1d ↗
39. 10.1016/j.jhep.2005.12.02710.1016/j.jhep.2005.12.027 ↗
40. 10.1016/j.jhep.2009.07.00910.1016/j.jhep.2009.07.009 ↗
41. 10.1016/S1015-9584(08)60056-110.1016/S1015-9584(08)60056-1 ↗
42. 10.1111/j.1349-7006.2003.tb01404.x10.1111/j.1349-7006.2003.tb01404.x ↗
43. 10.1111/j.1440-1746.2003.03256.x10.1111/j.1440-1746.2003.03256.x ↗
44. 10.1016/j.dld.2007.10.01110.1016/j.dld.2007.10.011 ↗
45. Kao WY, Chiou YY, Hung HH, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase–platelet ratio index. Eur J Gastroenterol Hepatol. 2011;23:528–536.
46. 10.1002/(SICI)1096-9071(199907)58:3<227::AID-JMV7>3.0.CO;2-710.1002/(SICI)1096-9071(199907)58:3<227::AID-JMV7>3.0.CO;2-7 ↗
47. 10.1111/j.1478-3231.2003.00871.x10.1111/j.1478-3231.2003.00871.x ↗
48. 10.1080/1365182031001583310.1080/13651820310015833 ↗
49. 10.1007/s12032-014-0883-x10.1007/s12032-014-0883-x ↗
50. 10.1371/journal.pone.002529510.1371/journal.pone.0025295 ↗